- Home
- TPCS vs OTLK Comparison
TPCS vs OTLK Comparison
Compare TPCS & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TPCS | OTLK |
|---|---|---|
| Founded | 1956 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.4M | 37.5M |
| IPO Year | 2008 | 2016 |
Fundamental Metrics
Financial Performance| Metric | TPCS | OTLK |
|---|---|---|
| Price | $3.99 | $0.40 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 29.6K | ★ 4.4M |
| Earning Date | 02-17-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 64.20 | 55.91 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $34,031,000.00 | $8,146,123.00 |
| Revenue This Year | N/A | $1,430.98 |
| Revenue Next Year | N/A | $173.23 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.72 | N/A |
| 52 Week Low | $2.88 | $0.16 |
| 52 Week High | $6.25 | $3.39 |
Technical Indicators
Market Signals| Indicator | TPCS | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 52.12 | 68.09 |
| Support Level | $3.67 | $0.18 |
| Resistance Level | $4.71 | $0.39 |
| Average True Range (ATR) | 0.19 | 0.04 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 37.30 | 57.11 |
Price Performance
Historical ComparisonAbout TPCS TechPrecision Corporation
Techprecision Corp manufactures metal fabricated and machined precision components and systems. It offers a full range of services required to transform raw materials into precision finished products. The company's products are used in markets including defense, aerospace, nuclear, medical, and precision industries. All of its operations and customers are located in the United States. The company have two wholly owned subsidiaries that are each reportable segments: Ranor and Stadco. Each reportable segment focuses on the manufacture and assembly of specific components. It derives maximum revenue from Ranor segment.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.